^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KDR mutation

i
Other names: KDR, CD309, FLK1, VEGFR, VEGFR2, Kinase insert domain receptor (a type III receptor tyrosine kinase)
Entrez ID:
Related biomarkers:
6ms
Clinicopathologic and molecular correlates to neoadjuvant chemotherapy-induced pathologic response in breast angiosarcoma. (PubMed, Genes Chromosomes Cancer)
However, NACT patients with MYC-amplified tumors showed better disease-free survival (p = 0.04) compared to MYC-amplified patients without NACT. The overall survival of NACT group correlated with size >10 cm (p = 0.02), pathologic response (p = 0.04), and multifocality (p = 0.01) by univariate, while only size >10 cm (p = 0.03) remained significant by multivariate analysis.
Journal
|
TMB (Tumor Mutational Burden) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • KDR (Kinase insert domain receptor)
|
MYC amplification • KDR mutation
7ms
Clinical characteristics, proteins, and genes related to interstitial pneumonia-associated squamous cell carcinoma of the lungs. (PubMed, Pathol Res Pract)
ERBB4 and KDR mutations were observed in both with or without IP, and these genes may be tumor-related genes in SCC. These molecular markers may help determine the prognoses of patients with SCC with IP and direct the development of treatment approaches.
Journal
|
KDR (Kinase insert domain receptor) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • STAT3 (Signal Transducer And Activator Of Transcription 3) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
FBXW7 mutation • STAT3 expression • KDR mutation
11ms
VE-cadherin junction dynamics in initial lymphatic vessels promotes lymph node metastasis. (PubMed, Life Sci Alliance)
We conclude that VEGFA mediates zippering of VE-cadherin junctions in initial lymphatics. Zippering is accompanied by increased VE-cadherin fragmentation through VEGFA-induced Src kinase activation, correlating with tumor dissemination to sentinel lymph nodes.
Journal
|
CDH5 (Cadherin 5)
|
EGFR mutation • VEGFA elevation • KDR expression • KDR mutation
1year
LIVER ANGIOSARCOMA IS ASSOCIATED WITH ARISTOLOCHIC ACID EXPOSURE AND HAS A DISTINCT TELOMERE MAINTENANCE MECHANISM (CTOS 2023)
Our study is the first to connect AA exposure to the etiology of liver AS. The high mutation rate and distinct telomere maintenance mechanism of liver AS provides insights into future treatments.
Clinical
|
TP53 (Tumor protein P53) • KDR (Kinase insert domain receptor) • ATRX (ATRX Chromatin Remodeler) • BUB1 (BUB1 Mitotic Checkpoint Serine/Threonine Kinase)
|
TP53 mutation • ATRX mutation • KDR mutation
1year
PRIMARY CARDIAC ANGIOSARCOMA- GENOMIC AND MOLECULAR LANDSCAPE (CTOS 2023)
Our results highlight the presence of KDR mutations in primary CAS that have been reported predominantly in primary breast AS in previous studies. Primary CAS is characterized by POT1 mutations, which have previously been reported only in CAS in Li-Fraumeni like families. We are limited by the small number of samples with RNAseq data to derive inferences about the immune profile of CAS, which is also confounded by chemotherapy administered to the patients prior to surgical resection.
Tumor mutational burden
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • KDR (Kinase insert domain receptor) • POT1 (Protection of telomeres 1) • RECQL (RecQ Like Helicase) • ZFHX4 (Zinc Finger Homeobox 4)
|
POT1 mutation • KDR mutation • KDR amplification
over1year
Primary cardiac angiosarcoma: a clinicopathological and molecular genetic analysis of thirteen cases (PubMed, Zhonghua Bing Li Xue Za Zhi)
Ki-67 index is helpful to assess the degree and grade of tumor differentiation. The occurrence and development of PCAS may be related to the pathway involved in KDR mutation, but KDR mutation has no clear correlation with clinicopathological characteristics of PCAS, and immunohistochemical staining can not replace gene detection to determine whether the tumor had KDR mutation.
Retrospective data • Journal
|
NF1 (Neurofibromin 1) • KDR (Kinase insert domain receptor) • CD34 (CD34 molecule) • VIM (Vimentin) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
|
EGFR mutation • NF1 mutation • KDR expression • KDR mutation
over1year
Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. (PubMed, J Pathol)
In summary, a significant proportion of HAS in Taiwan is associated with ESRD and harbors a distinctive mutational signature, which concomitantly links nephrotoxicity and mutagenesis resulting from the exposure to aristolochic acid or related compounds. High TMB may support the eligibility for immunotherapy in treating ESRD-associated HAS.
Journal • Tumor mutational burden • IO biomarker
|
TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • KDR (Kinase insert domain receptor) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
|
TMB-H • CDKN2A deletion • ATRX mutation • KDR mutation • KDR amplification • KDR amplification
over1year
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer. (ASCO 2023)
In ICI-treated bladder cancers, KDR mutation is associated with prolonged OS, higher TMB and activated antitumor immunity, which suggests that KDR mutation may serve as a potential biomarker to guide ICI therapy in bladder cancer.
Clinical • Checkpoint inhibition • Tumor mutational burden • IO biomarker
|
TMB (Tumor Mutational Burden) • KDR (Kinase insert domain receptor)
|
TMB-H • KDR mutation
almost2years
Histopathologic Grading Is of Prognostic Significance in Primary Angiosarcoma of Breast: Proposal of a Simplified 2-tier Grading System. (PubMed, Am J Surg Pathol)
Based on 2-tier system, the 5-year overall survival was 38% for high-grade angiosarcoma and 74% for low-grade angiosarcoma. PIK3CA mutations alone or concurrent with KDR alterations were identified in angiosarcomas with worse prognosis.
Journal
|
PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • KDR (Kinase insert domain receptor)
|
PIK3CA mutation • ERBB3 mutation • KDR mutation
over2years
Influence of KDR Genetic Variation on the Effectiveness and Safety of Bevacizumab in the First-Line Treatment for Patients with Advanced Colorectal Cancer. (PubMed, Int J Gen Med)
Additionally, in terms of safety, 55 patients experienced grade 2 or higher fatigue (incidence rate 40.74%) after receiving bevacizumab along with chemotherapy. The 889 C>T mutation in KDR gene affects the KDR expression in colorectal cancer patients, thereby affecting the effectiveness of bevacizumab therapy.
Journal
|
KDR (Kinase insert domain receptor)
|
KDR mutation
|
Avastin (bevacizumab)
over2years
Association of KDR mutation with better clinical outcomes in pan-cancer for immune checkpoint inhibitors. (PubMed, Am J Cancer Res)
Meanwhile, KDR mutation was indicative of an immune-hot status, characterized by higher expression of PD-L1 and abundance of cytotoxic lymphocytes. KDR mutations may be potential positive predictors for pan-cancer received ICIs.
Clinical data • Journal • Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • KDR (Kinase insert domain receptor)
|
TMB-H • PD-L1 overexpression • KDR mutation
over2years
Impacts of genotypic variants on survival following reoperation for recurrent glioblastoma. (PubMed, J Neurooncol)
Maximal safe re-resection significantly lengthens PPS regardless of genetic makeup, but reoperations are especially beneficial for IDH-WT rGBMs with EGFR and CDKN2A/B mutations with TP53-WT, and NF1-WT. Histopathology at recurrence may be an imperfect gauge of disease severity at progression and the imaging progression may be more reflective of the prognosis.
Journal
|
EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • KDR (Kinase insert domain receptor) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
|
TP53 mutation • EGFR mutation • TP53 wild-type • NF1 mutation • CDKN2A mutation • IDH wild-type • KDR mutation
|
Avastin (bevacizumab)
over2years
KDR mutation as novel biomarker for immune checkpoint inhibitors in pan-cancer (AACR 2022)
Our work demonstrates that KDR mutation has the potential to become a predictive biomarker for ICIs.
Checkpoint inhibition • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker • Pan tumor
|
PD-L1 (Programmed death ligand 1) • KDR (Kinase insert domain receptor)
|
EGFR mutation • PD-L1 overexpression • KDR mutation
over3years
Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. (PubMed, Cancer Lett)
Furthermore, activated VEGFR2 augments the dependence on glutamine (Gln) of melanoma cells, thus increasing Gln uptake and their sensitivity to Gln deprivation and to inhibitors of glutaminase, the enzyme initiating Gln metabolism by cells. Overall, these results highlight Gln addiction as a metabolic vulnerability of tumors harboring the activating VEGFR2 mutation and suggest novel therapeutic approaches for those patients harboring activating mutations of VEGFR2.
Journal
|
KDR (Kinase insert domain receptor)
|
EGFR mutation • KDR expression • KDR mutation